Primecap Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.48B Sell
9,223,432
-42,350
-0.5% -$42.9M 6.68% 1
2025
Q4
$9.96B Sell
9,265,782
-1,529,556
-14% -$1.46B 7.54% 1
2025
Q3
$8.24B Sell
10,795,338
-1,359,570
-11% -$1.01B 6.31% 1
2025
Q2
$9.48B Sell
12,154,908
-2,624,862
-18% -$2.04B 7.51% 1
2025
Q1
$12.2B Sell
14,779,770
-1,976,884
-12% -$1.64B 10.09% 1
2024
Q4
$12.9B Sell
16,756,654
-933,854
-5% -$773M 10.02% 1
2024
Q3
$15.7B Sell
17,690,508
-1,927,574
-10% -$1.73B 11.52% 1
2024
Q2
$17.8B Sell
19,618,082
-1,636,108
-8% -$1.31B 12.86% 1
2024
Q1
$16.5B Sell
21,254,190
-946,344
-4% -$673M 12.33% 1
2023
Q4
$12.9B Sell
22,200,534
-863,002
-4% -$504M 10.25% 1
2023
Q3
$12.4B Sell
23,063,536
-482,665
-2% -$249M 10.46% 1
2023
Q2
$11B Sell
23,546,201
-1,821,349
-7% -$764M 9.23% 1
2023
Q1
$8.71B Sell
25,367,550
-524,475
-2% -$177M 7.6% 1
2022
Q4
$9.47B Sell
25,892,025
-2,125,130
-8% -$753M 8.67% 1
2022
Q3
$9.06B Sell
28,017,155
-421,333
-1% -$133M 8.77% 1
2022
Q2
$9.22B Sell
28,438,488
-434,743
-2% -$130M 8.24% 1
2022
Q1
$8.27B Sell
28,873,231
-817,450
-3% -$210M 6.24% 1
2021
Q4
$8.2B Sell
29,690,681
-3,010,305
-9% -$763M 5.68% 1
2021
Q3
$7.56B Sell
32,700,986
-1,258,281
-4% -$311M 5.33% 1
2021
Q2
$7.79B Sell
33,959,267
-1,418,968
-4% -$285M 5.24% 1
2021
Q1
$6.61B Sell
35,378,235
-1,378,950
-4% -$270M 4.61% 1
2020
Q4
$6.21B Sell
36,757,185
-1,218,139
-3% -$182M 4.61% 1
2020
Q3
$5.62B Sell
37,975,324
-1,652,633
-4% -$256M 4.64% 1
2020
Q2
$6.51B Sell
39,627,957
-2,307,345
-6% -$354M 5.58% 1
2020
Q1
$5.82B Sell
41,935,302
-1,189,416
-3% -$163M 5.7% 1
2019
Q4
$5.67B Buy
43,124,718
+293,082
+0.7% +$34M 4.11% 1
2019
Q3
$4.79B Sell
42,831,636
-331,484
-0.8% -$36.9M 3.83% 1
2019
Q2
$4.78B Sell
43,163,120
-74,584
-0.2% -$8.78M 3.54% 2
2019
Q1
$5.61B Sell
43,237,704
-7,365,752
-15% -$896M 4.13% 1
2018
Q4
$5.86B Sell
50,603,456
-4,188,112
-8% -$468M 4.74% 1
2018
Q3
$5.88B Sell
54,791,568
-310,946
-0.6% -$31.1M 3.97% 1
2018
Q2
$4.7B Buy
55,102,514
+555,731
+1% +$45.6M 3.49% 2
2018
Q1
$4.22B Sell
54,546,783
-605,794
-1% -$48.8M 3.17% 2
2017
Q4
$4.66B Sell
55,152,577
-529,945
-1% -$45.1M 3.57% 2
2017
Q3
$4.76B Sell
55,682,522
-680,058
-1% -$55.8M 3.94% 2
2017
Q2
$4.64B Sell
56,362,580
-767,125
-1% -$62.6M 3.98% 1
2017
Q1
$4.81B Sell
57,129,705
-371,393
-0.6% -$29.7M 4.36% 1
2016
Q4
$4.23B Buy
57,501,098
+1,052,050
+2% +$78.3M 4.16% 2
2016
Q3
$4.53B Sell
56,449,048
-997,591
-2% -$79.8M 4.52% 2
2016
Q2
$4.52B Sell
57,446,639
-310,279
-0.5% -$23.4M 4.82% 1
2016
Q1
$4.16B Buy
57,756,918
+102,526
+0.2% +$7.76M 4.31% 3
2015
Q4
$4.86B Buy
57,654,392
+408,002
+0.7% +$33.9M 4.97% 1
2015
Q3
$4.79B Sell
57,246,390
-2,813,240
-5% -$238M 5.32% 1
2015
Q2
$5.01B Buy
60,059,630
+610,736
+1% +$46.5M 4.93% 2
2015
Q1
$4.32B Buy
59,448,894
+1,856,193
+3% +$132M 4.22% 3
2014
Q4
$3.97B Buy
57,592,701
+492,156
+0.9% +$33.2M 4.03% 3
2014
Q3
$3.7B Sell
57,100,545
-2,295
-0% -$145K 3.96% 3
2014
Q2
$3.55B Sell
57,102,840
-26,868
-0% -$1.6M 3.89% 3
2014
Q1
$3.36B Buy
57,129,708
+5,581,283
+11% +$311M 3.81% 3
2013
Q4
$2.63B Buy
51,548,425
+701,428
+1% +$35.1M 3.16% 6
2013
Q3
$2.56B Buy
50,846,997
+1,946,132
+4% +$102M 3.37% 5
2013
Q2
$2.4B Buy
+48,900,865
New +$2.66B 3.44% 5

Other funds holding LLY

Primecap Management's LLY Position: Q1 2026 in Review

Primecap Management reduced its Eli Lilly (LLY) stake by 0.46% in Q1 2026, selling an estimated $42.9M and leaving 9,223,432 shares worth $8.48B. The position accounts for 6.68% of the portfolio, ranked #1.

Primecap Management first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.8B in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Primecap Management held 9,223,432 shares of Eli Lilly worth $8.48B as of Q1 2026.
  • Primecap Management sold 42,350 Eli Lilly shares in Q1 2026, an estimated $42.9M.
  • Eli Lilly made up 6.68% of Primecap Management's portfolio in Q1 2026, its #1 holding.
  • Primecap Management first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Primecap Management's Eli Lilly position peaked at $17.8B in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Primecap Management's 13F filing for Q1 2026, filed 11 May 2026.